John Koreth Selected Research

Neoplasms (Cancer)

1/2022	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
12/2021	Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
10/2021	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
1/2021	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
1/2021	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
1/2019	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.
1/2018	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
8/2017	Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
5/2017	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
1/2017	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Koreth Research Topics

Disease

41	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2022 - 07/2007
31	Bronchiolitis Obliterans Syndrome 11/2022 - 04/2009
28	Neoplasms (Cancer) 01/2022 - 04/2008
14	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 05/2007
11	Leukemia 12/2022 - 05/2007
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 06/2009
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 01/2008
6	Multiple Myeloma 07/2022 - 02/2007
6	Lymphoma (Lymphomas) 01/2018 - 04/2008
4	Infections 01/2022 - 04/2012
4	Iron Overload 06/2012 - 05/2007
3	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2022 - 01/2019
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 01/2016
2	Injection Site Reaction 12/2022 - 11/2017
2	Hematuria 11/2022 - 12/2020
2	Viremia 01/2022 - 05/2010
2	Cytokine Release Syndrome 01/2022 - 01/2021
2	Inflammation (Inflammations) 11/2020 - 01/2018
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 01/2019
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 09/2013
2	Virus Diseases (Viral Diseases) 01/2020 - 08/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2017 - 04/2008
1	Bronchiolitis Obliterans 12/2022
1	Epistaxis (Nosebleed) 11/2022
1	Hypotension (Low Blood Pressure) 11/2022
1	Plasma Cell Leukemia 07/2022
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 04/2022
1	COVID-19 01/2021
1	Cytopenia 01/2021
1	Dysbiosis 11/2020
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2020
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2020
1	Communicable Diseases (Infectious Diseases) 03/2019
1	Hypersensitivity (Allergy) 03/2019
1	Disease Progression 01/2019
1	Thrombotic Microangiopathies 11/2018

Drug/Important Bio-Agent (IBA)

16	Tacrolimus (Prograf)FDA LinkGeneric 12/2022 - 07/2007
12	Sirolimus (Rapamycin)FDA Link 01/2020 - 07/2007
11	Interleukin-2 (IL2)IBA 11/2022 - 12/2011
8	Methotrexate (Mexate)FDA LinkGeneric 12/2022 - 07/2009
7	Bortezomib (Velcade)FDA Link 03/2019 - 10/2009
5	VaccinesIBA 12/2022 - 09/2009
5	SteroidsIBA 11/2022 - 05/2013
5	AntigensIBA 11/2020 - 09/2013
5	fludarabineIBA 01/2020 - 04/2008
5	Busulfan (Busulfex)FDA Link 01/2020 - 04/2008
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 09/2009
4	Proteins (Proteins, Gene)FDA Link 07/2016 - 12/2009
3	CytokinesIBA 01/2022 - 09/2013
3	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2021 - 01/2018
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2018
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 06/2013
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020 - 09/2010
3	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 05/2010
2	Alemtuzumab (Campath)FDA Link 04/2022 - 05/2013
2	ibrutinibIBA 12/2021 - 11/2014
2	IpilimumabIBA 10/2021 - 07/2016
2	Natalizumab (Tysabri)FDA Link 05/2021 - 01/2021
2	InterferonsIBA 12/2020 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 06/2012
2	Phosphotransferases (Kinase)IBA 01/2020 - 12/2008
2	Pharmaceutical PreparationsIBA 03/2019 - 01/2017
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 03/2019 - 05/2009
2	trans-crotonin (CTN)IBA 03/2019 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 11/2016
2	AntibodiesIBA 12/2017 - 03/2015
2	Biological ProductsIBA 11/2017 - 09/2009
2	Calcineurin InhibitorsIBA 09/2013 - 09/2009
2	Ferritins (Ferritin)IBA 06/2012 - 06/2011
2	IronIBA 06/2012 - 06/2011
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2022
1	ChromatinIBA 12/2022
1	ixazomibIBA 07/2022
1	tocilizumab (atlizumab)FDA Link 01/2022
1	venetoclaxIBA 12/2021
1	Progesterone FDA LinkGeneric 01/2021
1	Inositol (Myoinositol)IBA 01/2020
1	Maraviroc FDA Link 03/2019
1	Lenalidomide (CC 5013)FDA Link 01/2019
1	CreatinineIBA 01/2019
1	Melphalan (Alkeran)FDA LinkGeneric 01/2019
1	Co-Repressor ProteinsIBA 01/2019
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2018

Therapy/Procedure

50	Hematopoietic Stem Cell Transplantation 11/2022 - 05/2007
30	Therapeutics 11/2022 - 02/2007
23	Transplantation 10/2021 - 05/2007
20	Stem Cell Transplantation 01/2020 - 02/2007
12	Cell Transplantation 07/2022 - 08/2017
8	Homologous Transplantation 07/2022 - 04/2008
3	Autologous Transplantation 01/2019 - 02/2007
3	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 04/2016 - 07/2009
2	Immunotherapy 01/2022 - 09/2009
2	Platelet Transfusion (Blood Platelet Transfusions) 01/2020 - 01/2019
2	Drug Therapy (Chemotherapy) 01/2018 - 02/2007
1	Length of Stay 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Donor Selection 01/2021
1	Photopheresis 01/2019
1	Chemoradiotherapy 01/2018